

16 February 2015

NRC License Reviewer
Materials Licensing Branch
US Nuclear Regulatory Commission-Region III
2443 Warrenville Road, Suite 210
Lisle, IL 60532-4351

Re: Request to Decommission License No. 13-26640-01

Dear NRC License Reviewer:


Covance CRU requests that the above-referenced medical use license be decommissioned; this license was in the Specific Use Type 7C category and pertains to "uptake, dilution, and excretion studies permitted by 10 CFR 35.100", involving administration of only ^{14}C - or ^3H -radiolabeled drug materials. Since 24 Apr 2013, per Amendment No. 15, this license has been "in standby" status. As part of the historical record for the above-referenced license, Covance CRU has decommissioned the 2 previously "active" clinical sites, i.e., decommissioned the 800 St. Mary's Drive, Evansville, IN clinical site in 2008 (see license amendment No. 12) and decommissioned the One Waterfront Plaza, 500 Ala Moana Blvd., Suite 400, Honolulu, HI clinical site in 2013 (see license amendment No. 15). Since the time that the current 617 Oakley St., Evansville, IN clinical site was newly built and added in 2008 to this license (see license amendment No. 12) no radioactive material was received, possessed, or used at this specific clinical site; hence, its "in standby" status. Covance has made the corporate decision to no longer maintain this license, since all currently "active" medical use licensee activities are located at the Covance clinical site in Madison, WI (DHS License No. 025-1075-01).

We have included a completed NRC Form 314; however, since no radioactive materials have ever been procured or possessed for this remaining clinical site and since the only sealed sources ($\approx 20 \mu\text{Ci } ^{133}\text{Ba}$ source for calibrating liquid scintillation counter and $\approx 1 \mu\text{Ci } ^{137}\text{Cs}$ source for calibrating survey meter) do not require leak test and have never leaked, there is no supportive documents needed/attached. It is our understanding that there is no accompanying fee required for NRC evaluation of this license decommissioning request; if we are incorrect, please just let us know ASAP what the fee is so that we can forward you a check for the appropriate amount. Thank you in advance for your timely evaluation of this license amendment request.

Sincerely,



Theodore D. Broering, MBA
Executive Director, Clinical Pharmacology Services
Covance Clinical Research Unit, Inc.



Robert G. Kochan, PhD
Covance US Clinical Pharmacology RSO
Covance Clinical Research Unit, Inc.

Enclosure: Completed/signed Form NRC 314 (02-2014).

RECEIVED FEB 18 2015



CERTIFICATE OF DISPOSITION OF MATERIALS

Estimated burden per response to comply with this mandatory collection request: 30 minutes. This submittal is used by NRC as part of the basis for its determination that the facility is released for unrestricted use. Send comments regarding burden estimate to the FOIA, Privacy, and Information Collections Branch (T-5 F53), U.S. Nuclear Regulatory Commission, Washington, DC 20555-0001, or by internet e-mail to Infocollects.Resource@nrc.gov, and to the Desk Officer, Office of Information and Regulatory Affairs, NE08-10202, (3150-0028), Office of Management and Budget, Washington, DC 20503. If a means used to impose an information collection does not display a currently valid OMB control number, the NRC may not conduct or sponsor, and a person is not required to respond to, the information collection.

LICENSEE NAME AND ADDRESS Covance Clinical Research Unit, Inc. Global Clinical Pharmacology 617 Oakley Street Evansville, IN 47710	LICENSE NUMBER 13-26640-01	DOCKET NUMBER
	LICENSE EXPIRATION DATE 01/31/2016	

A. LICENSE STATUS (Check the appropriate box)

- This license has expired. This license has not yet expired; please terminate it.

B. DISPOSAL OF RADIOACTIVE MATERIAL

(Check the appropriate boxes and complete as necessary. If additional space is needed, provide attachments)

The licensee, or any individual executing this certificate on behalf of the licensee, certifies that:

- 1. No radioactive materials have ever been procured or possessed by the licensee under this license.
- 2. All activities authorized by this license have ceased, and all radioactive materials procured and/or possessed by the licensee under this license number cited above have been disposed of in the following manner.
 - a. Transfer of radioactive materials to the licensee listed below:

 - b. Disposal of radioactive materials:
 - 1. Directly by the licensee:

 - 2. By licensed disposal site:

 - 3. By waste contractor:
 - c. All radioactive materials have been removed such that any remaining residual radioactivity is within the limits of 10 CFR Part 20, Subpart E, and is ALARA.

C. SURVEYS PERFORMED AND REPORTED

- 1. A radiation survey was conducted by the licensee. The survey confirms:
 - a. the absence of licensed radioactive materials
 - b. that any remaining residual radioactivity is within the limits of 10 CFR 20, Subpart E, and is ALARA.
- 2. A copy of the radiation survey results:
 - a. is attached; or b. is not attached (Provide explanation); or c. was forwarded to NRC on: _____ Date
- 3. A radiation survey is not required as only sealed sources were ever possessed under this license, and
 - a. The results of the latest leak test are attached; and/or
 - b. No leaking sources have ever been identified.

The person to be contacted regarding the information provided on this form:

NAME	TITLE	TELEPHONE (Include Area Code)	E-MAIL ADDRESS
Robert G. Kochan, PhD	RSO	608-210-7668	robert.kochan@covance.com

Mail all future correspondence regarding this license to:

Robert G. Kochan, PhD (RSO); Covance Clinical Research Unit, Inc.; Global Clinical Pharmacology; Covance - Madison Clinical Research Unit; 3402 Kinsman Boulevard; Madison, WI 53704

C. CERTIFYING OFFICIAL

I CERTIFY UNDER PENALTY OF PERJURY THAT THE FOREGOING IS TRUE AND CORRECT

PRINTED NAME AND TITLE	SIGNATURE	DATE
Theodore D. Broering, MBA; Executive Director, Clinical Pharmacology Services; Covance Clinical Development Services		02/16/2015

WARNING: FALSE STATEMENTS IN THIS CERTIFICATE MAY BE SUBJECT TO CIVIL AND/OR CRIMINAL PENALTIES. NRC REGULATIONS REQUIRE THAT SUBMISSIONS TO THE NRC BE COMPLETE AND ACCURATE IN ALL MATERIAL RESPECT. 18 U.S.C. SECTION 1001 MAKES IT A CRIMINAL OFFENSE TO MAKE A WILLFULLY FALSE STATEMENT OR REPRESENTATION TO ANY DEPARTMENT OR AGENCY OF THE UNITED STATES AS TO ANY MATTER WITHIN ITS JURISDICTION.

